Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-01-07
1997-09-23
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514443, A61K 31445, A61K 3138
Patent
active
056705239
ABSTRACT:
A method of inhibiting musculoaponeurotic fibromatoses comprising administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is, optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
REFERENCES:
patent: 4418068 (1983-11-01), Jones
patent: 5393763 (1995-02-01), Black et al.
patent: 5457116 (1995-10-01), Black et al.
patent: 5574047 (1996-11-01), Bumol et al.
Hayry et al., Am. J. Clin. Pathol. 77(6), pp. 681-685 (Biosis abstract No. 75035377). 1982.
Sportiello et al., Cancer 67, No. 5, pp. 1443-1446 (Derwent abstract No. 91-16264) 1991.
Evans et al., Endocrinology 134(5), pp. 2282-2288 (Biosis abstract No. 97274419). 1994.
Brandi Maria Luisa
Tonelli Francesco
Boone David E.
Eli Lilly and Company
Henley III Raymond
Sales James J.
LandOfFree
Methods of inhibiting musculoaponeurotic fibromatoses (desmoid t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting musculoaponeurotic fibromatoses (desmoid t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting musculoaponeurotic fibromatoses (desmoid t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1938787